Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1-4 cross-sectional survey results.
Adolescent
Carrier State
/ prevention & control
Cross-Sectional Studies
Female
Humans
Incidence
Male
Meningococcal Infections
/ epidemiology
Meningococcal Vaccines
/ immunology
Neisseria meningitidis
Neisseria meningitidis, Serogroup C
Prevalence
Risk Factors
Serogroup
United Kingdom
/ epidemiology
Vaccination
Young Adult
Journal
The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
25
09
2019
revised:
16
06
2020
accepted:
13
10
2020
pubmed:
23
1
2021
medline:
18
5
2021
entrez:
22
1
2021
Statut:
ppublish
Résumé
The incidence of invasive meningococcal disease in the UK decreased by approximately four times from 1999 to 2014, with reductions in serogroup C and serogroup B disease. Lower serogroup C invasive meningococcal disease incidence was attributable to implementation of the meningococcal serogroup C conjugate vaccine in 1999, through direct and indirect protection, but no vaccine was implemented against serogroup B disease. UK Meningococcal Carriage surveys 1-3 (UKMenCar1-3), conducted in 1999, 2000, and 2001, were essential for understanding the impact of vaccination. To investigate the decline in invasive meningococcal disease incidence, we did a large oropharyngeal carriage survey in 2014-15, immediately before the changes to meningococcal vaccines in the UK national immunisation schedule. UKMenCar4 was a cross-sectional survey in adolescents aged 15-19 years who were enrolled from schools and colleges geographically local to one of 11 UK sampling centres between Sept 1, 2014, and March 30, 2015. Participants provided an oropharyngeal swab sample and completed a questionnaire on risk factors for carriage, including social behaviours. Samples were cultured for putative Neisseria spp, which were characterised with serogrouping and whole-genome sequencing. Data from this study were compared with the results from the UKMenCar1-3 surveys (1999-2001). From the 19 641 participants (11 332 female, 8242 male, 67 not stated) in UKMenCar4 with culturable swabs and completed risk-factor questionnaires, 1420 meningococci were isolated, with a carriage prevalence of 7·23% (95% CI 6·88-7·60). Carriage prevalence was substantially lower in UKMenCar4 than in the previous surveys: carriage prevalence was 16·6% (95% CI 15·89-17·22; 2306/13 901) in UKMenCar1 (1999), 17·6% (17·05-18·22; 2873/16 295) in UKMenCar2 (2000), and 18·7% (18·12-19·27; 3283/17 569) in UKMenCar3 (2001). Carriage prevalence was lower for all serogroups in UKMenCar4 than in UKMenCar1-3, except for serogroup Y, which was unchanged. The prevalence of carriage-promoting social behaviours decreased from 1999 to 2014-15, with individuals reporting regular cigarette smoking decreasing from 2932 (21·5%) of 13 650 to 2202 (11·2%) of 19 641, kissing in the past week from 6127 (44·8%) of 13 679 to 7320 (37·3%) of 19 641, and attendance at pubs and nightclubs in the past week from 8436 (62·1%) of 13 594 to 7662 (39·0%) of 19 641 (all p<0·0001). We show that meningococcal carriage prevalence in adolescents sampled nationally during a low incidence period (2014-15) was less than half of that in an equivalent population during a high incidence period (1999-2001). Disease and carriage caused by serogroup C was well controlled by ongoing vaccination. The prevalence of behaviours associated with carriage declined, suggesting that public health policies aimed at influencing behaviour might have further reduced disease. Wellcome Trust, UK Department of Health, and National Institute for Health Research.
Sections du résumé
BACKGROUND
The incidence of invasive meningococcal disease in the UK decreased by approximately four times from 1999 to 2014, with reductions in serogroup C and serogroup B disease. Lower serogroup C invasive meningococcal disease incidence was attributable to implementation of the meningococcal serogroup C conjugate vaccine in 1999, through direct and indirect protection, but no vaccine was implemented against serogroup B disease. UK Meningococcal Carriage surveys 1-3 (UKMenCar1-3), conducted in 1999, 2000, and 2001, were essential for understanding the impact of vaccination. To investigate the decline in invasive meningococcal disease incidence, we did a large oropharyngeal carriage survey in 2014-15, immediately before the changes to meningococcal vaccines in the UK national immunisation schedule.
METHODS
UKMenCar4 was a cross-sectional survey in adolescents aged 15-19 years who were enrolled from schools and colleges geographically local to one of 11 UK sampling centres between Sept 1, 2014, and March 30, 2015. Participants provided an oropharyngeal swab sample and completed a questionnaire on risk factors for carriage, including social behaviours. Samples were cultured for putative Neisseria spp, which were characterised with serogrouping and whole-genome sequencing. Data from this study were compared with the results from the UKMenCar1-3 surveys (1999-2001).
FINDINGS
From the 19 641 participants (11 332 female, 8242 male, 67 not stated) in UKMenCar4 with culturable swabs and completed risk-factor questionnaires, 1420 meningococci were isolated, with a carriage prevalence of 7·23% (95% CI 6·88-7·60). Carriage prevalence was substantially lower in UKMenCar4 than in the previous surveys: carriage prevalence was 16·6% (95% CI 15·89-17·22; 2306/13 901) in UKMenCar1 (1999), 17·6% (17·05-18·22; 2873/16 295) in UKMenCar2 (2000), and 18·7% (18·12-19·27; 3283/17 569) in UKMenCar3 (2001). Carriage prevalence was lower for all serogroups in UKMenCar4 than in UKMenCar1-3, except for serogroup Y, which was unchanged. The prevalence of carriage-promoting social behaviours decreased from 1999 to 2014-15, with individuals reporting regular cigarette smoking decreasing from 2932 (21·5%) of 13 650 to 2202 (11·2%) of 19 641, kissing in the past week from 6127 (44·8%) of 13 679 to 7320 (37·3%) of 19 641, and attendance at pubs and nightclubs in the past week from 8436 (62·1%) of 13 594 to 7662 (39·0%) of 19 641 (all p<0·0001).
INTERPRETATION
We show that meningococcal carriage prevalence in adolescents sampled nationally during a low incidence period (2014-15) was less than half of that in an equivalent population during a high incidence period (1999-2001). Disease and carriage caused by serogroup C was well controlled by ongoing vaccination. The prevalence of behaviours associated with carriage declined, suggesting that public health policies aimed at influencing behaviour might have further reduced disease.
FUNDING
Wellcome Trust, UK Department of Health, and National Institute for Health Research.
Identifiants
pubmed: 33482143
pii: S1473-3099(20)30842-2
doi: 10.1016/S1473-3099(20)30842-2
pmc: PMC8064914
pii:
doi:
Substances chimiques
Meningococcal Vaccines
0
serogroup C meningococcal conjugate vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
677-687Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Type : ErratumIn
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Références
Lancet Infect Dis. 2015 Nov;15(11):1334-46
pubmed: 26453240
Lancet. 2014 Jan 4;383(9911):40-47
pubmed: 24035220
J Hyg (Lond). 1918 Jul;17(2-3):350-65
pubmed: 20474675
Hum Vaccin Immunother. 2019;15(2):470-480
pubmed: 30296197
Arch Dis Child. 2016 Jan;101(1):91-5
pubmed: 26672098
Microbiology (Reading). 2012 Apr;158(Pt 4):1005-1015
pubmed: 22282518
Int J Epidemiol. 2019 Oct 1;48(5):1650-1664
pubmed: 30815691
Lancet. 2014 Dec 13;384(9960):2123-31
pubmed: 25145775
Lancet Infect Dis. 2010 Dec;10(12):853-61
pubmed: 21075057
BMC Genomics. 2014 Dec 18;15:1138
pubmed: 25523208
J Infect Dis. 2011 Oct 1;204(7):1046-53
pubmed: 21881120
Expert Rev Vaccines. 2009 Jul;8(7):851-61
pubmed: 19538112
Emerg Infect Dis. 2006 Jun;12(6):950-7
pubmed: 16707051
Clin Infect Dis. 2015 Feb 15;60(4):578-85
pubmed: 25389259
Wellcome Open Res. 2018 Sep 24;3:124
pubmed: 30345391
J Med Microbiol. 2006 Jul;55(Pt 7):887-896
pubmed: 16772416
Lancet Infect Dis. 2015 Dec;15(12):1420-8
pubmed: 26515523
Lancet. 2007 Jun 30;369(9580):2196-2210
pubmed: 17604802
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3140-5
pubmed: 9501229
Infect Genet Evol. 2008 Sep;8(5):558-65
pubmed: 18479979
Epidemiol Infect. 1987 Dec;99(3):591-601
pubmed: 3123263
N Engl J Med. 2020 Jan 23;382(4):318-327
pubmed: 31971677
J Infect Dis. 2008 Mar 1;197(5):737-43
pubmed: 18271745
Wellcome Open Res. 2019 Aug 6;4:118
pubmed: 31544158
Expert Rev Vaccines. 2019 Jan;18(1):15-30
pubmed: 30526162
Infect Dis Ther. 2019 Sep;8(3):307-333
pubmed: 31347097
Vaccine. 2009 Jun 24;27 Suppl 2:B51-63
pubmed: 19477562
Emerg Infect Dis. 2013 Apr;19(4):566-73
pubmed: 23628376
Lancet. 2002 May 25;359(9320):1829-31
pubmed: 12044380